Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a research report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating on the stock.

A number of other brokerages also recently issued reports on KROS. Scotiabank assumed coverage on Keros Therapeutics in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 price target for the company. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Guggenheim assumed coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a "buy" rating and a $96.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on Keros Therapeutics in a report on Thursday, October 24th. They issued an "overweight" rating for the company. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $89.11.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded up $2.63 on Tuesday, reaching $62.58. 322,659 shares of the company were exchanged, compared to its average volume of 368,598. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The company has a market cap of $2.35 billion, a P/E ratio of -12.20 and a beta of 1.23. The stock's 50 day moving average price is $56.87 and its 200-day moving average price is $51.89.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The company had revenue of $0.04 million for the quarter. During the same period in the previous year, the company posted ($1.27) earnings per share. On average, research analysts predict that Keros Therapeutics will post -4.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the second quarter worth approximately $128,000. Ameritas Investment Partners Inc. raised its stake in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock worth $169,000 after purchasing an additional 324 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter worth approximately $216,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.